KR20010086224A - Ｍｅｔｈ1 및 ｍｅｔｈ2 폴리뉴클레오티드 및 폴리펩티드 - Google Patents

Info

Publication number

KR20010086224A

KR20010086224A KR1020007008060A KR20007008060A KR20010086224A KR 20010086224 A KR20010086224 A KR 20010086224A KR 1020007008060 A KR1020007008060 A KR 1020007008060A KR 20007008060 A KR20007008060 A KR 20007008060A KR 20010086224 A KR20010086224 A KR 20010086224A

Authority

KR

South Korea

Prior art keywords

seq

polypeptide

amino acid

meth1

meth2

Prior art date

1998-01-23

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Ceased

Links

• Espacenet
• Global Dossier
• Discuss

• 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 395
• 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 374
• 229920001184 polypeptide Polymers 0.000 title claims abstract description 357
• 102000040430 polynucleotide Human genes 0.000 title claims description 163
• 108091033319 polynucleotide Proteins 0.000 title claims description 163
• 239000002157 polynucleotide Substances 0.000 title claims description 163
• 102100027398 A disintegrin and metalloproteinase with thrombospondin motifs 1 Human genes 0.000 claims abstract description 401
• 101000936405 Homo sapiens A disintegrin and metalloproteinase with thrombospondin motifs 1 Proteins 0.000 claims abstract description 400
• 101000730038 Homo sapiens A disintegrin and metalloproteinase with thrombospondin motifs 8 Proteins 0.000 claims abstract description 395
• 102100032635 A disintegrin and metalloproteinase with thrombospondin motifs 8 Human genes 0.000 claims abstract description 386
• 150000007523 nucleic acids Chemical class 0.000 claims abstract description 64
• 239000013598 vector Substances 0.000 claims abstract description 64
• 230000033115 angiogenesis Effects 0.000 claims abstract description 56
• 102000039446 nucleic acids Human genes 0.000 claims abstract description 54
• 108020004707 nucleic acids Proteins 0.000 claims abstract description 54
• 230000002401 inhibitory effect Effects 0.000 claims abstract description 26
• 150000001413 amino acids Chemical class 0.000 claims description 193
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 119
• 239000002299 complementary DNA Substances 0.000 claims description 103
• 125000003729 nucleotide group Chemical group 0.000 claims description 102
• 239000002773 nucleotide Substances 0.000 claims description 99
• 239000012634 fragment Substances 0.000 claims description 98
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 95
• 238000000034 method Methods 0.000 claims description 95
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 35
• 238000012217 deletion Methods 0.000 claims description 34
• 230000037430 deletion Effects 0.000 claims description 34
• 230000027455 binding Effects 0.000 claims description 31
• 238000006467 substitution reaction Methods 0.000 claims description 21
• 108091026890 Coding region Proteins 0.000 claims description 18
• 230000000295 complement effect Effects 0.000 claims description 13
• 230000004048 modification Effects 0.000 claims description 13
• 238000012986 modification Methods 0.000 claims description 13
• 238000004519 manufacturing process Methods 0.000 claims description 11
• 241000124008 Mammalia Species 0.000 claims description 8
• 238000004590 computer program Methods 0.000 claims description 6
• 239000011159 matrix material Substances 0.000 claims description 6
• 238000003780 insertion Methods 0.000 claims description 5
• 230000037431 insertion Effects 0.000 claims description 5
• 238000012258 culturing Methods 0.000 claims 1
• 108090000623 proteins and genes Proteins 0.000 abstract description 159
• 102000004169 proteins and genes Human genes 0.000 abstract description 119
• 241000282414 Homo sapiens Species 0.000 abstract description 35
• 206010028980 Neoplasm Diseases 0.000 abstract description 22
• 230000001965 increasing effect Effects 0.000 abstract description 15
• 201000011510 cancer Diseases 0.000 abstract description 13
• 238000002560 therapeutic procedure Methods 0.000 abstract description 5
• 238000004393 prognosis Methods 0.000 abstract description 4
• 238000010188 recombinant method Methods 0.000 abstract description 4
• 238000002405 diagnostic procedure Methods 0.000 abstract description 3
• 210000004027 cell Anatomy 0.000 description 132
• 235000001014 amino acid Nutrition 0.000 description 129
• 229940024606 amino acid Drugs 0.000 description 119
• 235000018102 proteins Nutrition 0.000 description 118
• 102100036034 Thrombospondin-1 Human genes 0.000 description 68
• 108020004414 DNA Proteins 0.000 description 60
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 47
• 230000014509 gene expression Effects 0.000 description 40
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 37
• 238000012360 testing method Methods 0.000 description 37
• 102000037865 fusion proteins Human genes 0.000 description 36
• 108020001507 fusion proteins Proteins 0.000 description 36
• 230000000694 effects Effects 0.000 description 34
• 201000010099 disease Diseases 0.000 description 32
• 101000659879 Homo sapiens Thrombospondin-1 Proteins 0.000 description 30
• 239000013615 primer Substances 0.000 description 30
• 210000001519 tissue Anatomy 0.000 description 27
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 26
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 26
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 26
• 238000003556 assay Methods 0.000 description 26
• 238000004458 analytical method Methods 0.000 description 25
• 108020004999 messenger RNA Proteins 0.000 description 25
• 101710159964 Tail sheath protein Proteins 0.000 description 24
• 101710168563 Tail spike protein Proteins 0.000 description 24
• 235000019801 trisodium phosphate Nutrition 0.000 description 24
• 108010006035 Metalloproteases Proteins 0.000 description 22
• 102000005741 Metalloproteases Human genes 0.000 description 22
• 238000003752 polymerase chain reaction Methods 0.000 description 22
• 238000000746 purification Methods 0.000 description 21
• 239000002585 base Substances 0.000 description 20
• 210000004899 c-terminal region Anatomy 0.000 description 20
• 125000000539 amino acid group Chemical group 0.000 description 19
• 230000000890 antigenic effect Effects 0.000 description 19
• 239000013612 plasmid Substances 0.000 description 19
• 239000000523 sample Substances 0.000 description 19
• 101800001224 Disintegrin Proteins 0.000 description 18
• 239000013604 expression vector Substances 0.000 description 18
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 18
• 239000008188 pellet Substances 0.000 description 18
• 239000000243 solution Substances 0.000 description 18
• 230000035755 proliferation Effects 0.000 description 17
• 108010076504 Protein Sorting Signals Proteins 0.000 description 16
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 16
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 16
• 238000007792 addition Methods 0.000 description 16
• 230000028993 immune response Effects 0.000 description 16
• 239000002609 medium Substances 0.000 description 16
• 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 15
• 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 15
• 238000010367 cloning Methods 0.000 description 15
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 15
• 208000035475 disorder Diseases 0.000 description 15
• 239000000203 mixture Substances 0.000 description 15
• 239000002953 phosphate buffered saline Substances 0.000 description 15
• 239000000047 product Substances 0.000 description 15
• 238000011282 treatment Methods 0.000 description 15
• 108010046722 Thrombospondin 1 Proteins 0.000 description 14
• 208000011580 syndromic disease Diseases 0.000 description 14
• 241000588724 Escherichia coli Species 0.000 description 13
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 13
• 239000011780 sodium chloride Substances 0.000 description 13
• 102000053602 DNA Human genes 0.000 description 12
• 241000700605 Viruses Species 0.000 description 12
• 230000001580 bacterial effect Effects 0.000 description 12
• 210000002889 endothelial cell Anatomy 0.000 description 12
• 238000001727 in vivo Methods 0.000 description 12
• 238000002360 preparation method Methods 0.000 description 12
• 238000003776 cleavage reaction Methods 0.000 description 11
• 235000018417 cysteine Nutrition 0.000 description 11
• 238000009396 hybridization Methods 0.000 description 11
• 230000003463 hyperproliferative effect Effects 0.000 description 11
• 230000002163 immunogen Effects 0.000 description 11
• 208000015181 infectious disease Diseases 0.000 description 11
• 230000007017 scission Effects 0.000 description 11
• 102100027399 A disintegrin and metalloproteinase with thrombospondin motifs 2 Human genes 0.000 description 10
• 101710100366 A disintegrin and metalloproteinase with thrombospondin motifs 2 Proteins 0.000 description 10
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 10
• 241001465754 Metazoa Species 0.000 description 10
• 239000012472 biological sample Substances 0.000 description 10
• 210000000349 chromosome Anatomy 0.000 description 10
• 150000001875 compounds Chemical class 0.000 description 10
• 210000004087 cornea Anatomy 0.000 description 10
• PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 10
• 230000005764 inhibitory process Effects 0.000 description 10
• 239000003550 marker Substances 0.000 description 10
• 108091008146 restriction endonucleases Proteins 0.000 description 10
• 239000006228 supernatant Substances 0.000 description 10
• 101000633605 Homo sapiens Thrombospondin-2 Proteins 0.000 description 9
• 108700026244 Open Reading Frames Proteins 0.000 description 9
• 102100029529 Thrombospondin-2 Human genes 0.000 description 9
• 230000004927 fusion Effects 0.000 description 9
• 230000002068 genetic effect Effects 0.000 description 9
• 239000003112 inhibitor Substances 0.000 description 9
• 210000004962 mammalian cell Anatomy 0.000 description 9
• 230000008569 process Effects 0.000 description 9
• 241000701447 unidentified baculovirus Species 0.000 description 9
• 241000894006 Bacteria Species 0.000 description 8
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
• 108060003951 Immunoglobulin Proteins 0.000 description 8
• 241000699666 Mus <mouse, genus> Species 0.000 description 8
• 208000027418 Wounds and injury Diseases 0.000 description 8
• 230000002491 angiogenic effect Effects 0.000 description 8
• 239000000427 antigen Substances 0.000 description 8
• 108091007433 antigens Proteins 0.000 description 8
• 102000036639 antigens Human genes 0.000 description 8
• 210000004408 hybridoma Anatomy 0.000 description 8
• 102000018358 immunoglobulin Human genes 0.000 description 8
• 208000014674 injury Diseases 0.000 description 8
• 230000001404 mediated effect Effects 0.000 description 8
• 210000000056 organ Anatomy 0.000 description 8
• 230000004044 response Effects 0.000 description 8
• 238000001890 transfection Methods 0.000 description 8
• 206010061218 Inflammation Diseases 0.000 description 7
• 238000000636 Northern blotting Methods 0.000 description 7
• 108091034057 RNA (poly(A)) Proteins 0.000 description 7
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 7
• 108091081024 Start codon Proteins 0.000 description 7
• 210000001744 T-lymphocyte Anatomy 0.000 description 7
• 230000004071 biological effect Effects 0.000 description 7
• 210000001772 blood platelet Anatomy 0.000 description 7
• 230000003399 chemotactic effect Effects 0.000 description 7
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 7
• 238000002474 experimental method Methods 0.000 description 7
• 230000006870 function Effects 0.000 description 7
• 238000000338 in vitro Methods 0.000 description 7
• 230000004054 inflammatory process Effects 0.000 description 7
• 102000006495 integrins Human genes 0.000 description 7
• 108010044426 integrins Proteins 0.000 description 7
• 108010082117 matrigel Proteins 0.000 description 7
• 238000012545 processing Methods 0.000 description 7
• 230000001105 regulatory effect Effects 0.000 description 7
• 230000003248 secreting effect Effects 0.000 description 7
• 238000002864 sequence alignment Methods 0.000 description 7
• 210000003491 skin Anatomy 0.000 description 7
• 239000001632 sodium acetate Substances 0.000 description 7
• 235000017281 sodium acetate Nutrition 0.000 description 7
• 239000000126 substance Substances 0.000 description 7
• 102000004190 Enzymes Human genes 0.000 description 6
• 108090000790 Enzymes Proteins 0.000 description 6
• 241000238631 Hexapoda Species 0.000 description 6
• 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 6
• 108091034117 Oligonucleotide Proteins 0.000 description 6
• 239000011543 agarose gel Substances 0.000 description 6
• 230000015572 biosynthetic process Effects 0.000 description 6
• 210000004204 blood vessel Anatomy 0.000 description 6
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
• 238000004113 cell culture Methods 0.000 description 6
• 238000005119 centrifugation Methods 0.000 description 6
• 230000002759 chromosomal effect Effects 0.000 description 6
• 238000001514 detection method Methods 0.000 description 6
• 238000003745 diagnosis Methods 0.000 description 6
• 230000004069 differentiation Effects 0.000 description 6
• 231100000673 dose–response relationship Toxicity 0.000 description 6
• 238000005516 engineering process Methods 0.000 description 6
• 229940088598 enzyme Drugs 0.000 description 6
• 210000002950 fibroblast Anatomy 0.000 description 6
• 230000002209 hydrophobic effect Effects 0.000 description 6
• 210000002865 immune cell Anatomy 0.000 description 6
• 229930182817 methionine Natural products 0.000 description 6
• 229960004452 methionine Drugs 0.000 description 6
• 230000008488 polyadenylation Effects 0.000 description 6
• 210000002966 serum Anatomy 0.000 description 6
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
• 208000023275 Autoimmune disease Diseases 0.000 description 5
• 241000283690 Bos taurus Species 0.000 description 5
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
• 206010052428 Wound Diseases 0.000 description 5
• 101710112987 Zinc metalloproteinase-disintegrin-like crotastatin Proteins 0.000 description 5
• 239000005557 antagonist Substances 0.000 description 5
• 230000000903 blocking effect Effects 0.000 description 5
• 239000000872 buffer Substances 0.000 description 5
• 229910052799 carbon Inorganic materials 0.000 description 5
• 239000003795 chemical substances by application Substances 0.000 description 5
• 230000035605 chemotaxis Effects 0.000 description 5
• 230000006378 damage Effects 0.000 description 5
• 239000000499 gel Substances 0.000 description 5
• 230000012010 growth Effects 0.000 description 5
• 239000003102 growth factor Substances 0.000 description 5
• 229960004198 guanidine Drugs 0.000 description 5
• 229960000789 guanidine hydrochloride Drugs 0.000 description 5
• 210000004072 lung Anatomy 0.000 description 5
• 238000005259 measurement Methods 0.000 description 5
• 239000012528 membrane Substances 0.000 description 5
• 102000005962 receptors Human genes 0.000 description 5
• 108020003175 receptors Proteins 0.000 description 5
• 230000008929 regeneration Effects 0.000 description 5
• 238000011069 regeneration method Methods 0.000 description 5
• 239000000725 suspension Substances 0.000 description 5
• 238000013518 transcription Methods 0.000 description 5
• 230000035897 transcription Effects 0.000 description 5
• 230000008733 trauma Effects 0.000 description 5
• 230000006444 vascular growth Effects 0.000 description 5
• 241000972773 Aulopiformes Species 0.000 description 4
• 101100230428 Caenorhabditis elegans hil-5 gene Proteins 0.000 description 4
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
• 208000009329 Graft vs Host Disease Diseases 0.000 description 4
• 108010093488 His-His-His-His-His-His Proteins 0.000 description 4
• 108090000144 Human Proteins Proteins 0.000 description 4
• 102000003839 Human Proteins Human genes 0.000 description 4
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
• 241000699670 Mus sp. Species 0.000 description 4
• 239000004677 Nylon Substances 0.000 description 4
• 239000004365 Protease Substances 0.000 description 4
• 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 4
• 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 4
• 230000003321 amplification Effects 0.000 description 4
• 229940121369 angiogenesis inhibitor Drugs 0.000 description 4
• 239000004037 angiogenesis inhibitor Substances 0.000 description 4
• 230000008901 benefit Effects 0.000 description 4
• 210000001124 body fluid Anatomy 0.000 description 4
• 239000010839 body fluid Substances 0.000 description 4
• 210000004556 brain Anatomy 0.000 description 4
• 230000004663 cell proliferation Effects 0.000 description 4
• 230000008859 change Effects 0.000 description 4
• 239000003153 chemical reaction reagent Substances 0.000 description 4
• 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 4
• 230000007812 deficiency Effects 0.000 description 4
• 239000002158 endotoxin Substances 0.000 description 4
• 239000012894 fetal calf serum Substances 0.000 description 4
• 238000002873 global sequence alignment Methods 0.000 description 4
• 208000024908 graft versus host disease Diseases 0.000 description 4
• 210000002216 heart Anatomy 0.000 description 4
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
• 210000003917 human chromosome Anatomy 0.000 description 4
• 229940072221 immunoglobulins Drugs 0.000 description 4
• 238000011534 incubation Methods 0.000 description 4
• 230000000977 initiatory effect Effects 0.000 description 4
• 230000003993 interaction Effects 0.000 description 4
• 238000002955 isolation Methods 0.000 description 4
• 210000003041 ligament Anatomy 0.000 description 4
• 239000003446 ligand Substances 0.000 description 4
• 150000002632 lipids Chemical class 0.000 description 4
• 210000004379 membrane Anatomy 0.000 description 4
• 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 4
• 229960000485 methotrexate Drugs 0.000 description 4
• 230000005012 migration Effects 0.000 description 4
• 238000013508 migration Methods 0.000 description 4
• 230000035772 mutation Effects 0.000 description 4
• 238000003199 nucleic acid amplification method Methods 0.000 description 4
• 229920001778 nylon Polymers 0.000 description 4
• 229920000642 polymer Polymers 0.000 description 4
• 239000013641 positive control Substances 0.000 description 4
• 239000002987 primer (paints) Substances 0.000 description 4
• 230000004952 protein activity Effects 0.000 description 4
• 230000002797 proteolythic effect Effects 0.000 description 4
• 230000002829 reductive effect Effects 0.000 description 4
• 230000010076 replication Effects 0.000 description 4
• 210000003705 ribosome Anatomy 0.000 description 4
• 235000019515 salmon Nutrition 0.000 description 4
• 238000012163 sequencing technique Methods 0.000 description 4
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 4
• 210000005166 vasculature Anatomy 0.000 description 4
• 238000005406 washing Methods 0.000 description 4
• NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 3
• 108091022885 ADAM Proteins 0.000 description 3
• 102000029791 ADAM Human genes 0.000 description 3
• 208000030507 AIDS Diseases 0.000 description 3
• 102000053028 CD36 Antigens Human genes 0.000 description 3
• 108010045374 CD36 Antigens Proteins 0.000 description 3
• 208000035473 Communicable disease Diseases 0.000 description 3
• 102000004127 Cytokines Human genes 0.000 description 3
• 108090000695 Cytokines Proteins 0.000 description 3
• 239000003155 DNA primer Substances 0.000 description 3
• 238000001712 DNA sequencing Methods 0.000 description 3
• 229920002307 Dextran Polymers 0.000 description 3
• 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
• 108010024636 Glutathione Proteins 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• 206010020751 Hypersensitivity Diseases 0.000 description 3
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
• 201000009906 Meningitis Diseases 0.000 description 3
• 241001420836 Ophthalmitis Species 0.000 description 3
• 208000001388 Opportunistic Infections Diseases 0.000 description 3
• 102000035195 Peptidases Human genes 0.000 description 3
• 108091005804 Peptidases Proteins 0.000 description 3
• 206010035226 Plasma cell myeloma Diseases 0.000 description 3
• 206010035664 Pneumonia Diseases 0.000 description 3
• 108020004511 Recombinant DNA Proteins 0.000 description 3
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
• 238000012300 Sequence Analysis Methods 0.000 description 3
• 238000002105 Southern blotting Methods 0.000 description 3
• 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 3
• 239000007983 Tris buffer Substances 0.000 description 3
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
• 208000025865 Ulcer Diseases 0.000 description 3
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
• 230000005856 abnormality Effects 0.000 description 3
• 239000002253 acid Substances 0.000 description 3
• 210000004100 adrenal gland Anatomy 0.000 description 3
• 229960003767 alanine Drugs 0.000 description 3
• 235000004279 alanine Nutrition 0.000 description 3
• -1 aliphatic amino acid Chemical class 0.000 description 3
• 229960000723 ampicillin Drugs 0.000 description 3
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
• 230000001772 anti-angiogenic effect Effects 0.000 description 3
• CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
• 210000000988 bone and bone Anatomy 0.000 description 3
• 210000000069 breast epithelial cell Anatomy 0.000 description 3
• 238000004422 calculation algorithm Methods 0.000 description 3
• 238000001516 cell proliferation assay Methods 0.000 description 3
• 238000006243 chemical reaction Methods 0.000 description 3
• 238000002512 chemotherapy Methods 0.000 description 3
• 125000004122 cyclic group Chemical group 0.000 description 3
• 238000011161 development Methods 0.000 description 3
• 230000018109 developmental process Effects 0.000 description 3
• 229960002086 dextran Drugs 0.000 description 3
• 238000009826 distribution Methods 0.000 description 3
• 230000003511 endothelial effect Effects 0.000 description 3
• 239000000284 extract Substances 0.000 description 3
• 210000001508 eye Anatomy 0.000 description 3
• 238000002509 fluorescent in situ hybridization Methods 0.000 description 3
• 238000010230 functional analysis Methods 0.000 description 3
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
• 239000001963 growth medium Substances 0.000 description 3
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
• 230000002439 hemostatic effect Effects 0.000 description 3
• 229960002897 heparin Drugs 0.000 description 3
• 229920000669 heparin Polymers 0.000 description 3
• 238000012188 high-throughput screening assay Methods 0.000 description 3
• 208000026278 immune system disease Diseases 0.000 description 3
• 210000003000 inclusion body Anatomy 0.000 description 3
• 239000000411 inducer Substances 0.000 description 3
• 239000012678 infectious agent Substances 0.000 description 3
• 206010022000 influenza Diseases 0.000 description 3
• 238000002347 injection Methods 0.000 description 3
• 239000007924 injection Substances 0.000 description 3
• 229930027917 kanamycin Natural products 0.000 description 3
• 229960000318 kanamycin Drugs 0.000 description 3
• SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
• 229930182823 kanamycin A Natural products 0.000 description 3
• 210000003734 kidney Anatomy 0.000 description 3
• 239000008101 lactose Substances 0.000 description 3
• 230000000670 limiting effect Effects 0.000 description 3
• 210000004185 liver Anatomy 0.000 description 3
• 238000013507 mapping Methods 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• 210000002464 muscle smooth vascular Anatomy 0.000 description 3
• 238000002703 mutagenesis Methods 0.000 description 3
• 231100000350 mutagenesis Toxicity 0.000 description 3
• 201000000050 myeloid neoplasm Diseases 0.000 description 3
• 239000013642 negative control Substances 0.000 description 3
• 210000001672 ovary Anatomy 0.000 description 3
• 210000000496 pancreas Anatomy 0.000 description 3
• 208000010403 panophthalmitis Diseases 0.000 description 3
• 230000001575 pathological effect Effects 0.000 description 3
• 239000008194 pharmaceutical composition Substances 0.000 description 3
• 239000000546 pharmaceutical excipient Substances 0.000 description 3
• 210000002826 placenta Anatomy 0.000 description 3
• 239000002244 precipitate Substances 0.000 description 3
• 230000002062 proliferating effect Effects 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 206010039073 rheumatoid arthritis Diseases 0.000 description 3
• 230000028327 secretion Effects 0.000 description 3
• 239000011734 sodium Substances 0.000 description 3
• 125000006850 spacer group Chemical group 0.000 description 3
• 230000004936 stimulating effect Effects 0.000 description 3
• 238000003860 storage Methods 0.000 description 3
• 210000002435 tendon Anatomy 0.000 description 3
• 230000002537 thrombolytic effect Effects 0.000 description 3
• 210000001685 thyroid gland Anatomy 0.000 description 3
• 238000013519 translation Methods 0.000 description 3
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
• 229960004799 tryptophan Drugs 0.000 description 3
• 201000008827 tuberculosis Diseases 0.000 description 3
• 231100000397 ulcer Toxicity 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
• 229920001817 Agar Polymers 0.000 description 2
• 108010088751 Albumins Proteins 0.000 description 2
• 102000009027 Albumins Human genes 0.000 description 2
• 108700028369 Alleles Proteins 0.000 description 2
• 101100208237 Bos taurus THBS2 gene Proteins 0.000 description 2
• 241000282693 Cercopithecidae Species 0.000 description 2
• 108091033380 Coding strand Proteins 0.000 description 2
• 108020004705 Codon Proteins 0.000 description 2
• 102100038385 Coiled-coil domain-containing protein R3HCC1L Human genes 0.000 description 2
• 206010009944 Colon cancer Diseases 0.000 description 2
• 108020004635 Complementary DNA Proteins 0.000 description 2
• 206010010741 Conjunctivitis Diseases 0.000 description 2
• 206010010904 Convulsion Diseases 0.000 description 2
• 241000699802 Cricetulus griseus Species 0.000 description 2
• 241000701022 Cytomegalovirus Species 0.000 description 2
• 102000012410 DNA Ligases Human genes 0.000 description 2
• 108010061982 DNA Ligases Proteins 0.000 description 2
• 206010012689 Diabetic retinopathy Diseases 0.000 description 2
• 102100024746 Dihydrofolate reductase Human genes 0.000 description 2
• 108700021041 Disintegrin Proteins 0.000 description 2
• 238000002965 ELISA Methods 0.000 description 2
• 241000196324 Embryophyta Species 0.000 description 2
• 241001131785 Escherichia coli HB101 Species 0.000 description 2
• 206010016654 Fibrosis Diseases 0.000 description 2
• 241000233866 Fungi Species 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 2
• 108020005350 Initiator Codon Proteins 0.000 description 2
• 108091092195 Intron Proteins 0.000 description 2
• 108010025815 Kanamycin Kinase Proteins 0.000 description 2
• 101100288095 Klebsiella pneumoniae neo gene Proteins 0.000 description 2
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
• 208000019693 Lung disease Diseases 0.000 description 2
• 206010027476 Metastases Diseases 0.000 description 2
• 229930193140 Neomycin Natural products 0.000 description 2
• BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
• 101710182846 Polyhedrin Proteins 0.000 description 2
• 102100038567 Properdin Human genes 0.000 description 2
• 108010005642 Properdin Proteins 0.000 description 2
• 201000004681 Psoriasis Diseases 0.000 description 2
• 101710086015 RNA ligase Proteins 0.000 description 2
• 206010063837 Reperfusion injury Diseases 0.000 description 2
• 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
• 206010039491 Sarcoma Diseases 0.000 description 2
• 108091058545 Secretory proteins Proteins 0.000 description 2
• 102000040739 Secretory proteins Human genes 0.000 description 2
• 208000019802 Sexually transmitted disease Diseases 0.000 description 2
• 108020004682 Single-Stranded DNA Proteins 0.000 description 2
• 239000004283 Sodium sorbate Substances 0.000 description 2
• 241000187747 Streptomyces Species 0.000 description 2
• 108090000787 Subtilisin Proteins 0.000 description 2
• 108010022394 Threonine synthase Proteins 0.000 description 2
• 108060008245 Thrombospondin Proteins 0.000 description 2
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
• 201000005485 Toxoplasmosis Diseases 0.000 description 2
• 108700009124 Transcription Initiation Site Proteins 0.000 description 2
• 239000013504 Triton X-100 Substances 0.000 description 2
• 229920004890 Triton X-100 Polymers 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 108010006886 Vitrogen Proteins 0.000 description 2
• HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 2
• 210000001015 abdomen Anatomy 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 239000008272 agar Substances 0.000 description 2
• 230000002776 aggregation Effects 0.000 description 2
• 239000000556 agonist Substances 0.000 description 2
• 208000026935 allergic disease Diseases 0.000 description 2
• 239000002870 angiogenesis inducing agent Substances 0.000 description 2
• 230000006427 angiogenic response Effects 0.000 description 2
• 230000005875 antibody response Effects 0.000 description 2
• YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
• 206010003246 arthritis Diseases 0.000 description 2
• 208000006673 asthma Diseases 0.000 description 2
• 230000001363 autoimmune Effects 0.000 description 2
• 210000003719 b-lymphocyte Anatomy 0.000 description 2
• 239000011324 bead Substances 0.000 description 2
• 108010005774 beta-Galactosidase Proteins 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• 210000004369 blood Anatomy 0.000 description 2
• 239000008280 blood Substances 0.000 description 2
• 210000000481 breast Anatomy 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• 229910000389 calcium phosphate Inorganic materials 0.000 description 2
• 235000011010 calcium phosphates Nutrition 0.000 description 2
• 238000004364 calculation method Methods 0.000 description 2
• 210000000170 cell membrane Anatomy 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 208000015114 central nervous system disease Diseases 0.000 description 2
• 210000003837 chick embryo Anatomy 0.000 description 2
• 210000004252 chorionic villi Anatomy 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 230000015271 coagulation Effects 0.000 description 2
• 238000005345 coagulation Methods 0.000 description 2
• 239000000356 contaminant Substances 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 238000012937 correction Methods 0.000 description 2
• 238000004132 cross linking Methods 0.000 description 2
• 230000007547 defect Effects 0.000 description 2
• 230000006735 deficit Effects 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 206010012601 diabetes mellitus Diseases 0.000 description 2
• 238000000502 dialysis Methods 0.000 description 2
• 102000004419 dihydrofolate reductase Human genes 0.000 description 2
• 108020001096 dihydrofolate reductase Proteins 0.000 description 2
• 238000010790 dilution Methods 0.000 description 2
• 239000012895 dilution Substances 0.000 description 2
• 239000003814 drug Substances 0.000 description 2
• 239000003937 drug carrier Substances 0.000 description 2
• 208000001848 dysentery Diseases 0.000 description 2
• 230000002500 effect on skin Effects 0.000 description 2
• 210000002257 embryonic structure Anatomy 0.000 description 2
• 239000003623 enhancer Substances 0.000 description 2
• 238000009585 enzyme analysis Methods 0.000 description 2
• 210000002919 epithelial cell Anatomy 0.000 description 2
• 239000013613 expression plasmid Substances 0.000 description 2
• 238000000605 extraction Methods 0.000 description 2
• 235000019688 fish Nutrition 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
• 238000009472 formulation Methods 0.000 description 2
• 230000002538 fungal effect Effects 0.000 description 2
• 238000007429 general method Methods 0.000 description 2
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
• 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
• 150000003278 haem Chemical class 0.000 description 2
• 230000011132 hemopoiesis Effects 0.000 description 2
• 208000006454 hepatitis Diseases 0.000 description 2
• 231100000283 hepatitis Toxicity 0.000 description 2
• 238000004128 high performance liquid chromatography Methods 0.000 description 2
• 230000033444 hydroxylation Effects 0.000 description 2
• 238000005805 hydroxylation reaction Methods 0.000 description 2
• 230000009610 hypersensitivity Effects 0.000 description 2
• 230000003053 immunization Effects 0.000 description 2
• 238000002649 immunization Methods 0.000 description 2
• 230000001976 improved effect Effects 0.000 description 2
• 238000011065 in-situ storage Methods 0.000 description 2
• 230000006698 induction Effects 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 230000002757 inflammatory effect Effects 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 201000001441 melanoma Diseases 0.000 description 2
• 230000009401 metastasis Effects 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 210000003205 muscle Anatomy 0.000 description 2
• 230000014399 negative regulation of angiogenesis Effects 0.000 description 2
• 229960004927 neomycin Drugs 0.000 description 2
• 210000005036 nerve Anatomy 0.000 description 2
• 230000007935 neutral effect Effects 0.000 description 2
• 230000003472 neutralizing effect Effects 0.000 description 2
• 210000000440 neutrophil Anatomy 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 244000045947 parasite Species 0.000 description 2
• 208000033808 peripheral neuropathy Diseases 0.000 description 2
• 230000002688 persistence Effects 0.000 description 2
• 230000003285 pharmacodynamic effect Effects 0.000 description 2
• 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
• 210000002381 plasma Anatomy 0.000 description 2
• 239000013600 plasmid vector Substances 0.000 description 2
• 238000006116 polymerization reaction Methods 0.000 description 2
• 239000011148 porous material Substances 0.000 description 2
• 230000001323 posttranslational effect Effects 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 238000011002 quantification Methods 0.000 description 2
• 238000003127 radioimmunoassay Methods 0.000 description 2
• 239000011541 reaction mixture Substances 0.000 description 2
• 238000011084 recovery Methods 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 239000011347 resin Substances 0.000 description 2
• 229920005989 resin Polymers 0.000 description 2
• 238000010839 reverse transcription Methods 0.000 description 2
• 150000003839 salts Chemical class 0.000 description 2
• 210000002027 skeletal muscle Anatomy 0.000 description 2
• 208000017520 skin disease Diseases 0.000 description 2
• 210000001626 skin fibroblast Anatomy 0.000 description 2
• 210000000813 small intestine Anatomy 0.000 description 2
• 239000001509 sodium citrate Substances 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 230000000392 somatic effect Effects 0.000 description 2
• 210000004988 splenocyte Anatomy 0.000 description 2
• 238000003756 stirring Methods 0.000 description 2
• 210000002784 stomach Anatomy 0.000 description 2
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
• 238000001356 surgical procedure Methods 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• 210000001550 testis Anatomy 0.000 description 2
• 206010043554 thrombocytopenia Diseases 0.000 description 2
• 230000017423 tissue regeneration Effects 0.000 description 2
• 239000003053 toxin Substances 0.000 description 2
• 231100000765 toxin Toxicity 0.000 description 2
• 108700012359 toxins Proteins 0.000 description 2
• 238000012546 transfer Methods 0.000 description 2
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
• 238000010798 ubiquitination Methods 0.000 description 2
• 230000034512 ubiquitination Effects 0.000 description 2
• 241001430294 unidentified retrovirus Species 0.000 description 2
• 210000000626 ureter Anatomy 0.000 description 2
• 210000002700 urine Anatomy 0.000 description 2
• 230000002792 vascular Effects 0.000 description 2
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
• 238000001262 western blot Methods 0.000 description 2
• 230000029663 wound healing Effects 0.000 description 2
• DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
• KUHSEZKIEJYEHN-BXRBKJIMSA-N (2s)-2-amino-3-hydroxypropanoic acid;(2s)-2-aminopropanoic acid Chemical compound C[C@H](N)C(O)=O.OC[C@H](N)C(O)=O KUHSEZKIEJYEHN-BXRBKJIMSA-N 0.000 description 1
• PSLCKQYQNVNTQI-BHFSHLQUSA-N (2s)-2-aminobutanedioic acid;(2s)-2-aminopentanedioic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CCC(O)=O PSLCKQYQNVNTQI-BHFSHLQUSA-N 0.000 description 1
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
• NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
• FMYBFLOWKQRBST-UHFFFAOYSA-N 2-[bis(carboxymethyl)amino]acetic acid;nickel Chemical compound [Ni].OC(=O)CN(CC(O)=O)CC(O)=O FMYBFLOWKQRBST-UHFFFAOYSA-N 0.000 description 1
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
• BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
• ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
• RHAXKFFKGZJUOE-UHFFFAOYSA-N 7-acetyl-6-ethyl-3,5,8-trihydroxy-9,10-dioxoanthracene-1,2-dicarboxylic acid Chemical compound O=C1C2=CC(O)=C(C(O)=O)C(C(O)=O)=C2C(=O)C2=C1C(O)=C(CC)C(C(C)=O)=C2O RHAXKFFKGZJUOE-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• 108091022879 ADAMTS Proteins 0.000 description 1
• 102000029750 ADAMTS Human genes 0.000 description 1
• 108091005660 ADAMTS1 Proteins 0.000 description 1
• 230000005730 ADP ribosylation Effects 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
• 241000606750 Actinobacillus Species 0.000 description 1
• 102000007469 Actins Human genes 0.000 description 1
• 108010085238 Actins Proteins 0.000 description 1
• 108010059616 Activins Proteins 0.000 description 1
• 102000005606 Activins Human genes 0.000 description 1
• ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• 208000004881 Amebiasis Diseases 0.000 description 1
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
• 206010001980 Amoebiasis Diseases 0.000 description 1
• 206010002198 Anaphylactic reaction Diseases 0.000 description 1
• 241000272814 Anser sp. Species 0.000 description 1
• 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
• 241000712891 Arenavirus Species 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 201000002909 Aspergillosis Diseases 0.000 description 1
• 208000036641 Aspergillus infections Diseases 0.000 description 1
• 206010003591 Ataxia Diseases 0.000 description 1
• 241001203868 Autographa californica Species 0.000 description 1
• 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 1
• 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
• 241000193830 Bacillus <bacterium> Species 0.000 description 1
• 241000193738 Bacillus anthracis Species 0.000 description 1
• 208000031729 Bacteremia Diseases 0.000 description 1
• 241000606125 Bacteroides Species 0.000 description 1
• 241000335423 Blastomyces Species 0.000 description 1
• 241000588807 Bordetella Species 0.000 description 1
• 241000589968 Borrelia Species 0.000 description 1
• 208000003508 Botulism Diseases 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• 206010006448 Bronchiolitis Diseases 0.000 description 1
• 206010006500 Brucellosis Diseases 0.000 description 1
• 208000011691 Burkitt lymphomas Diseases 0.000 description 1
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
• 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 241000589876 Campylobacter Species 0.000 description 1
• 241000222122 Candida albicans Species 0.000 description 1
• 206010007134 Candida infections Diseases 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 108010078791 Carrier Proteins Proteins 0.000 description 1
• 206010007882 Cellulitis Diseases 0.000 description 1
• 108010012236 Chemokines Proteins 0.000 description 1
• 102000019034 Chemokines Human genes 0.000 description 1
• 201000006082 Chickenpox Diseases 0.000 description 1
• 241001227713 Chiron Species 0.000 description 1
• 241000606161 Chlamydia Species 0.000 description 1
• 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
• 208000032544 Cicatrix Diseases 0.000 description 1
• 241001533384 Circovirus Species 0.000 description 1
• 241000193403 Clostridium Species 0.000 description 1
• 208000003495 Coccidiosis Diseases 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010022452 Collagen Type I Proteins 0.000 description 1
• 102000012422 Collagen Type I Human genes 0.000 description 1
• 102100036213 Collagen alpha-2(I) chain Human genes 0.000 description 1
• 206010010099 Combined immunodeficiency Diseases 0.000 description 1
• 208000032170 Congenital Abnormalities Diseases 0.000 description 1
• 108091035707 Consensus sequence Proteins 0.000 description 1
• 239000004128 Copper(II) sulphate Substances 0.000 description 1
• 241000711573 Coronaviridae Species 0.000 description 1
• 241000186216 Corynebacterium Species 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 208000008953 Cryptosporidiosis Diseases 0.000 description 1
• 206010011502 Cryptosporidiosis infection Diseases 0.000 description 1
• KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
• 101150074155 DHFR gene Proteins 0.000 description 1
• 230000007023 DNA restriction-modification system Effects 0.000 description 1
• 201000004624 Dermatitis Diseases 0.000 description 1
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
• 101800000620 Disintegrin-like Proteins 0.000 description 1
• 208000009514 Dourine Diseases 0.000 description 1
• 238000001061 Dunnett's test Methods 0.000 description 1
• 208000032928 Dyslipidaemia Diseases 0.000 description 1
• 238000012286 ELISA Assay Methods 0.000 description 1
• 241000588921 Enterobacteriaceae Species 0.000 description 1
• YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 206010015150 Erythema Diseases 0.000 description 1
• 241001596967 Escherichia coli M15 Species 0.000 description 1
• 241000701959 Escherichia virus Lambda Species 0.000 description 1
• 208000001860 Eye Infections Diseases 0.000 description 1
• 229910016870 Fe(NO3)3-9H2O Inorganic materials 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 241000192125 Firmicutes Species 0.000 description 1
• 241000710831 Flavivirus Species 0.000 description 1
• 206010016952 Food poisoning Diseases 0.000 description 1
• 208000019331 Foodborne disease Diseases 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 206010018364 Glomerulonephritis Diseases 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 239000004366 Glucose oxidase Substances 0.000 description 1
• 108010015776 Glucose oxidase Proteins 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 244000068988 Glycine max Species 0.000 description 1
• 235000010469 Glycine max Nutrition 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 206010018612 Gonorrhoea Diseases 0.000 description 1
• 208000024869 Goodpasture syndrome Diseases 0.000 description 1
• 208000003807 Graves Disease Diseases 0.000 description 1
• 208000015023 Graves' disease Diseases 0.000 description 1
• 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
• 239000001922 Gum ghatti Substances 0.000 description 1
• 208000031886 HIV Infections Diseases 0.000 description 1
• 208000037357 HIV infectious disease Diseases 0.000 description 1
• 206010061192 Haemorrhagic fever Diseases 0.000 description 1
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
• 206010019196 Head injury Diseases 0.000 description 1
• 241000589989 Helicobacter Species 0.000 description 1
• 101710154606 Hemagglutinin Proteins 0.000 description 1
• 208000009889 Herpes Simplex Diseases 0.000 description 1
• 208000007514 Herpes zoster Diseases 0.000 description 1
• 101000743767 Homo sapiens Coiled-coil domain-containing protein R3HCC1L Proteins 0.000 description 1
• 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 description 1
• 101000829419 Homo sapiens Spermatogenic leucine zipper protein 1 Proteins 0.000 description 1
• 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
• 241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
• 208000023105 Huntington disease Diseases 0.000 description 1
• 206010062767 Hypophysitis Diseases 0.000 description 1
• 101150017040 I gene Proteins 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
• 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
• 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
• 206010021531 Impetigo Diseases 0.000 description 1
• 206010061216 Infarction Diseases 0.000 description 1
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
• 229930010555 Inosine Natural products 0.000 description 1
• UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 102000000589 Interleukin-1 Human genes 0.000 description 1
• 108010002352 Interleukin-1 Proteins 0.000 description 1
• 102100020881 Interleukin-1 alpha Human genes 0.000 description 1
• 108010082786 Interleukin-1alpha Proteins 0.000 description 1
• 206010023076 Isosporiasis Diseases 0.000 description 1
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
• 229930182816 L-glutamine Natural products 0.000 description 1
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• 108090001090 Lectins Proteins 0.000 description 1
• 102000004856 Lectins Human genes 0.000 description 1
• 208000004023 Legionellosis Diseases 0.000 description 1
• 241000713666 Lentivirus Species 0.000 description 1
• 206010024229 Leprosy Diseases 0.000 description 1
• 206010024238 Leptospirosis Diseases 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 208000017170 Lipid metabolism disease Diseases 0.000 description 1
• 241000186781 Listeria Species 0.000 description 1
• 206010067125 Liver injury Diseases 0.000 description 1
• 208000004852 Lung Injury Diseases 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• 208000016604 Lyme disease Diseases 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• 206010025327 Lymphopenia Diseases 0.000 description 1
• 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 108700020482 Maltose-Binding protein Proteins 0.000 description 1
• 206010026749 Mania Diseases 0.000 description 1
• 108091027974 Mature messenger RNA Proteins 0.000 description 1
• 201000005505 Measles Diseases 0.000 description 1
• PKVZBNCYEICAQP-UHFFFAOYSA-N Mecamylamine hydrochloride Chemical compound Cl.C1CC2C(C)(C)C(NC)(C)C1C2 PKVZBNCYEICAQP-UHFFFAOYSA-N 0.000 description 1
• 102000003792 Metallothionein Human genes 0.000 description 1
• 108090000157 Metallothionein Proteins 0.000 description 1
• 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
• 208000005647 Mumps Diseases 0.000 description 1
• 101100278853 Mus musculus Dhfr gene Proteins 0.000 description 1
• 101100015391 Mus musculus Ralgds gene Proteins 0.000 description 1
• 241000186359 Mycobacterium Species 0.000 description 1
• 241000204031 Mycoplasma Species 0.000 description 1
• 230000004988 N-glycosylation Effects 0.000 description 1
• 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
• 238000005481 NMR spectroscopy Methods 0.000 description 1
• 206010028851 Necrosis Diseases 0.000 description 1
• 241000588653 Neisseria Species 0.000 description 1
• 241001045988 Neogene Species 0.000 description 1
• 206010061309 Neoplasm progression Diseases 0.000 description 1
• 208000009869 Neu-Laxova syndrome Diseases 0.000 description 1
• 206010029240 Neuritis Diseases 0.000 description 1
• 206010029333 Neurosis Diseases 0.000 description 1
• 101100202932 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) tsp-4 gene Proteins 0.000 description 1
• 101100202938 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) tsp-5 gene Proteins 0.000 description 1
• 244000061176 Nicotiana tabacum Species 0.000 description 1
• 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
• 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
• 101710163270 Nuclease Proteins 0.000 description 1
• 206010030216 Oesophagitis Diseases 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 208000001132 Osteoporosis Diseases 0.000 description 1
• 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
• 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
• 206010033128 Ovarian cancer Diseases 0.000 description 1
• 206010061535 Ovarian neoplasm Diseases 0.000 description 1
• 238000012408 PCR amplification Methods 0.000 description 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
• 108090000526 Papain Proteins 0.000 description 1
• 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
• 206010033971 Paratyphoid fever Diseases 0.000 description 1
• 208000018737 Parkinson disease Diseases 0.000 description 1
• 241000606860 Pasteurella Species 0.000 description 1
• 206010034107 Pasteurella infections Diseases 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 102000057297 Pepsin A Human genes 0.000 description 1
• 108090000284 Pepsin A Proteins 0.000 description 1
• 208000010886 Peripheral nerve injury Diseases 0.000 description 1
• 201000005702 Pertussis Diseases 0.000 description 1
• 241000286209 Phasianidae Species 0.000 description 1
• 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
• 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
• 208000000474 Poliomyelitis Diseases 0.000 description 1
• 108010039918 Polylysine Proteins 0.000 description 1
• 239000004237 Ponceau 6R Substances 0.000 description 1
• 208000002787 Pregnancy Complications Diseases 0.000 description 1
• 108010050808 Procollagen Proteins 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
• 101710176177 Protein A56 Proteins 0.000 description 1
• 241000125945 Protoparvovirus Species 0.000 description 1
• 241000589516 Pseudomonas Species 0.000 description 1
• 206010037549 Purpura Diseases 0.000 description 1
• 241001672981 Purpura Species 0.000 description 1
• 102000009609 Pyrophosphatases Human genes 0.000 description 1
• 108010009413 Pyrophosphatases Proteins 0.000 description 1
• 206010037742 Rabies Diseases 0.000 description 1
• 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
• 101100208249 Rattus norvegicus Thbs4 gene Proteins 0.000 description 1
• 108020005091 Replication Origin Proteins 0.000 description 1
• 241000702670 Rotavirus Species 0.000 description 1
• BFDMCHRDSYTOLE-UHFFFAOYSA-N SC#N.NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 Chemical compound SC#N.NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 BFDMCHRDSYTOLE-UHFFFAOYSA-N 0.000 description 1
• 241000607142 Salmonella Species 0.000 description 1
• 206010039587 Scarlet Fever Diseases 0.000 description 1
• 108091081021 Sense strand Proteins 0.000 description 1
• 206010053879 Sepsis syndrome Diseases 0.000 description 1
• 206010040070 Septic Shock Diseases 0.000 description 1
• 241000607720 Serratia Species 0.000 description 1
• 239000001744 Sodium fumarate Substances 0.000 description 1
• 208000029033 Spinal Cord disease Diseases 0.000 description 1
• 241000256248 Spodoptera Species 0.000 description 1
• 102100036428 Spondin-1 Human genes 0.000 description 1
• 101710092167 Spondin-1 Proteins 0.000 description 1
• 241000191940 Staphylococcus Species 0.000 description 1
• 239000004138 Stearyl citrate Substances 0.000 description 1
• 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 108010006785 Taq Polymerase Proteins 0.000 description 1
• 208000000491 Tendinopathy Diseases 0.000 description 1
• 206010043255 Tendonitis Diseases 0.000 description 1
• 108020005038 Terminator Codon Proteins 0.000 description 1
• 208000024313 Testicular Neoplasms Diseases 0.000 description 1
• 206010057644 Testis cancer Diseases 0.000 description 1
• 206010043376 Tetanus Diseases 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• 101000609272 Thermobifida fusca (strain YX) Phenylacetone monooxygenase Proteins 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 208000007536 Thrombosis Diseases 0.000 description 1
• 102000002938 Thrombospondin Human genes 0.000 description 1
• 102000006601 Thymidine Kinase Human genes 0.000 description 1
• 108020004440 Thymidine kinase Proteins 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
• 206010069363 Traumatic lung injury Diseases 0.000 description 1
• 241000224526 Trichomonas Species 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
• 208000037386 Typhoid Diseases 0.000 description 1
• 206010046788 Uterine haemorrhage Diseases 0.000 description 1
• 206010046851 Uveitis Diseases 0.000 description 1
• 206010046865 Vaccinia virus infection Diseases 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• 206010046980 Varicella Diseases 0.000 description 1
• 206010058874 Viraemia Diseases 0.000 description 1
• 108020005202 Viral DNA Proteins 0.000 description 1
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
• 206010048038 Wound infection Diseases 0.000 description 1
• 241000607734 Yersinia <bacteria> Species 0.000 description 1
• 101710204001 Zinc metalloprotease Proteins 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 230000021736 acetylation Effects 0.000 description 1
• 238000006640 acetylation reaction Methods 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000000488 activin Substances 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 230000010933 acylation Effects 0.000 description 1
• 238000005917 acylation reaction Methods 0.000 description 1
• 201000001256 adenosarcoma Diseases 0.000 description 1
• 239000000853 adhesive Substances 0.000 description 1
• 230000001070 adhesive effect Effects 0.000 description 1
• 210000000577 adipose tissue Anatomy 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 238000009098 adjuvant therapy Methods 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 238000000246 agarose gel electrophoresis Methods 0.000 description 1
• 238000005054 agglomeration Methods 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 201000009961 allergic asthma Diseases 0.000 description 1
• 239000001164 aluminium sulphate Substances 0.000 description 1
• 230000009435 amidation Effects 0.000 description 1
• 238000007112 amidation reaction Methods 0.000 description 1
• 230000006229 amino acid addition Effects 0.000 description 1
• BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
• 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
• 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
• 235000011130 ammonium sulphate Nutrition 0.000 description 1
• 238000012197 amplification kit Methods 0.000 description 1
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
• 230000036783 anaphylactic response Effects 0.000 description 1
• 208000003455 anaphylaxis Diseases 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 238000005571 anion exchange chromatography Methods 0.000 description 1
• 239000003957 anion exchange resin Substances 0.000 description 1
• 150000001450 anions Chemical class 0.000 description 1
• 238000000137 annealing Methods 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000000692 anti-sense effect Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 230000009830 antibody antigen interaction Effects 0.000 description 1
• 230000036528 appetite Effects 0.000 description 1
• 235000019789 appetite Nutrition 0.000 description 1
• 229940114079 arachidonic acid Drugs 0.000 description 1
• 235000021342 arachidonic acid Nutrition 0.000 description 1
• 230000010516 arginylation Effects 0.000 description 1
• 108010062796 arginyllysine Proteins 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
• 229960005261 aspartic acid Drugs 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 239000000440 bentonite Substances 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 102000005936 beta-Galactosidase Human genes 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 208000015294 blood coagulation disease Diseases 0.000 description 1
• 201000001383 blood group incompatibility Diseases 0.000 description 1
• 208000014759 blood platelet disease Diseases 0.000 description 1
• 208000016363 blood protein disease Diseases 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 238000006664 bond formation reaction Methods 0.000 description 1
• 210000005013 brain tissue Anatomy 0.000 description 1
• 239000004161 brilliant blue FCF Substances 0.000 description 1
• 239000007853 buffer solution Substances 0.000 description 1
• 238000010804 cDNA synthesis Methods 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000001201 calcium disodium ethylene diamine tetra-acetate Substances 0.000 description 1
• 239000000279 calcium ferrocyanide Substances 0.000 description 1
• 239000001527 calcium lactate Substances 0.000 description 1
• 239000001362 calcium malate Substances 0.000 description 1
• 239000004330 calcium propionate Substances 0.000 description 1
• 239000001175 calcium sulphate Substances 0.000 description 1
• 239000001427 calcium tartrate Substances 0.000 description 1
• 201000003984 candidiasis Diseases 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 229910002091 carbon monoxide Inorganic materials 0.000 description 1
• 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 210000000845 cartilage Anatomy 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 238000005277 cation exchange chromatography Methods 0.000 description 1
• 239000003729 cation exchange resin Substances 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 208000026106 cerebrovascular disease Diseases 0.000 description 1
• 230000003196 chaotropic effect Effects 0.000 description 1
• 238000001311 chemical methods and process Methods 0.000 description 1
• 238000007385 chemical modification Methods 0.000 description 1
• 210000000038 chest Anatomy 0.000 description 1
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
• 210000001136 chorion Anatomy 0.000 description 1
• 230000001149 cognitive effect Effects 0.000 description 1
• 230000001427 coherent effect Effects 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 238000010835 comparative analysis Methods 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 230000004154 complement system Effects 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 238000011109 contamination Methods 0.000 description 1
• ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
• 238000002316 cosmetic surgery Methods 0.000 description 1
• SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
• SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
• RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
• HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
• NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 239000007857 degradation product Substances 0.000 description 1
• 230000017858 demethylation Effects 0.000 description 1
• 238000010520 demethylation reaction Methods 0.000 description 1
• 238000004925 denaturation Methods 0.000 description 1
• 230000036425 denaturation Effects 0.000 description 1
• 229960000633 dextran sulfate Drugs 0.000 description 1
• 238000002050 diffraction method Methods 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• 210000002249 digestive system Anatomy 0.000 description 1
• 239000012470 diluted sample Substances 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 239000000539 dimer Substances 0.000 description 1
• 206010013023 diphtheria Diseases 0.000 description 1
• 231100000676 disease causative agent Toxicity 0.000 description 1
• 239000004193 disodium 5'-ribonucleotide Substances 0.000 description 1
• 239000004198 disodium guanylate Substances 0.000 description 1
• 239000006196 drop Substances 0.000 description 1
• 229940079593 drug Drugs 0.000 description 1
• 238000007876 drug discovery Methods 0.000 description 1
• 241001493065 dsRNA viruses Species 0.000 description 1
• 230000001516 effect on protein Effects 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 230000013020 embryo development Effects 0.000 description 1
• 206010014599 encephalitis Diseases 0.000 description 1
• 206010014665 endocarditis Diseases 0.000 description 1
• 230000002124 endocrine Effects 0.000 description 1
• 210000003372 endocrine gland Anatomy 0.000 description 1
• 230000002357 endometrial effect Effects 0.000 description 1
• 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
• 210000003989 endothelium vascular Anatomy 0.000 description 1
• 238000004146 energy storage Methods 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 210000003979 eosinophil Anatomy 0.000 description 1
• 230000008556 epithelial cell proliferation Effects 0.000 description 1
• 230000008472 epithelial growth Effects 0.000 description 1
• 238000011067 equilibration Methods 0.000 description 1
• 231100000321 erythema Toxicity 0.000 description 1
• 210000003743 erythrocyte Anatomy 0.000 description 1
• 208000006881 esophagitis Diseases 0.000 description 1
• 235000020776 essential amino acid Nutrition 0.000 description 1
• 239000003797 essential amino acid Substances 0.000 description 1
• 238000012869 ethanol precipitation Methods 0.000 description 1
• 210000003527 eukaryotic cell Anatomy 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 208000030533 eye disease Diseases 0.000 description 1
• 208000011323 eye infectious disease Diseases 0.000 description 1
• 238000000855 fermentation Methods 0.000 description 1
• 230000004151 fermentation Effects 0.000 description 1
• 239000004222 ferrous gluconate Substances 0.000 description 1
• 239000012091 fetal bovine serum Substances 0.000 description 1
• 239000000835 fiber Substances 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 150000002211 flavins Chemical class 0.000 description 1
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
• 235000013373 food additive Nutrition 0.000 description 1
• 239000002778 food additive Substances 0.000 description 1
• 235000019249 food preservative Nutrition 0.000 description 1
• 239000005452 food preservative Substances 0.000 description 1
• 210000003953 foreskin Anatomy 0.000 description 1
• 230000022244 formylation Effects 0.000 description 1
• 238000006170 formylation reaction Methods 0.000 description 1
• 230000037433 frameshift Effects 0.000 description 1
• 230000006251 gamma-carboxylation Effects 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 238000002523 gelfiltration Methods 0.000 description 1
• 102000034356 gene-regulatory proteins Human genes 0.000 description 1
• 108091006104 gene-regulatory proteins Proteins 0.000 description 1
• 208000007565 gingivitis Diseases 0.000 description 1
• 210000004907 gland Anatomy 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 229940116332 glucose oxidase Drugs 0.000 description 1
• 235000019420 glucose oxidase Nutrition 0.000 description 1
• 239000004247 glycine and its sodium salt Substances 0.000 description 1
• 230000013595 glycosylation Effects 0.000 description 1
• 238000006206 glycosylation reaction Methods 0.000 description 1
• 208000001786 gonorrhea Diseases 0.000 description 1
• 239000006451 grace's insect medium Substances 0.000 description 1
• 239000003630 growth substance Substances 0.000 description 1
• ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
• 230000003394 haemopoietic effect Effects 0.000 description 1
• 230000037308 hair color Effects 0.000 description 1
• 238000003306 harvesting Methods 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 201000011066 hemangioma Diseases 0.000 description 1
• 201000001505 hemoglobinuria Diseases 0.000 description 1
• 208000007475 hemolytic anemia Diseases 0.000 description 1
• 230000002008 hemorrhagic effect Effects 0.000 description 1
• 230000023597 hemostasis Effects 0.000 description 1
• 231100000234 hepatic damage Toxicity 0.000 description 1
• 210000003494 hepatocyte Anatomy 0.000 description 1
• 238000000703 high-speed centrifugation Methods 0.000 description 1
• 210000003630 histaminocyte Anatomy 0.000 description 1
• 201000008298 histiocytosis Diseases 0.000 description 1
• 238000002744 homologous recombination Methods 0.000 description 1
• 230000006801 homologous recombination Effects 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 102000049483 human SPZ1 Human genes 0.000 description 1
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
• 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
• 230000005965 immune activity Effects 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 230000005847 immunogenicity Effects 0.000 description 1
• 230000016784 immunoglobulin production Effects 0.000 description 1
• 238000012151 immunohistochemical method Methods 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 238000007901 in situ hybridization Methods 0.000 description 1
• 230000000415 inactivating effect Effects 0.000 description 1
• 239000004179 indigotine Substances 0.000 description 1
• 229910052738 indium Inorganic materials 0.000 description 1
• APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
• 230000007574 infarction Effects 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 108091006086 inhibitor proteins Proteins 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 229960003786 inosine Drugs 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 230000008611 intercellular interaction Effects 0.000 description 1
• 208000028774 intestinal disease Diseases 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 230000000302 ischemic effect Effects 0.000 description 1
• 229960000310 isoleucine Drugs 0.000 description 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
• BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 239000000231 karaya gum Substances 0.000 description 1
• 206010023332 keratitis Diseases 0.000 description 1
• 238000011813 knockout mouse model Methods 0.000 description 1
• 101150109249 lacI gene Proteins 0.000 description 1
• 150000002597 lactoses Chemical class 0.000 description 1
• 239000002523 lectin Substances 0.000 description 1
• 231100000225 lethality Toxicity 0.000 description 1
• 229960003136 leucine Drugs 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
• 238000007834 ligase chain reaction Methods 0.000 description 1
• 238000001638 lipofection Methods 0.000 description 1
• 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 238000009630 liquid culture Methods 0.000 description 1
• 201000007270 liver cancer Diseases 0.000 description 1
• 210000005229 liver cell Anatomy 0.000 description 1
• 230000008818 liver damage Effects 0.000 description 1
• 208000019423 liver disease Diseases 0.000 description 1
• 208000014018 liver neoplasm Diseases 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 201000005202 lung cancer Diseases 0.000 description 1
• 231100000515 lung injury Toxicity 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 206010025135 lupus erythematosus Diseases 0.000 description 1
• 210000004324 lymphatic system Anatomy 0.000 description 1
• 231100001023 lymphopenia Toxicity 0.000 description 1
• 229960003646 lysine Drugs 0.000 description 1
• 235000018977 lysine Nutrition 0.000 description 1
• 201000000564 macroglobulinemia Diseases 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 239000001755 magnesium gluconate Substances 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 201000004792 malaria Diseases 0.000 description 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
• 210000001161 mammalian embryo Anatomy 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 238000013160 medical therapy Methods 0.000 description 1
• 230000006996 mental state Effects 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
• 230000011987 methylation Effects 0.000 description 1
• 238000007069 methylation reaction Methods 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 235000010755 mineral Nutrition 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 239000002808 molecular sieve Substances 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 239000010413 mother solution Substances 0.000 description 1
• 201000006417 multiple sclerosis Diseases 0.000 description 1
• 208000010805 mumps infectious disease Diseases 0.000 description 1
• 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
• 206010028417 myasthenia gravis Diseases 0.000 description 1
• 210000000066 myeloid cell Anatomy 0.000 description 1
• 208000010125 myocardial infarction Diseases 0.000 description 1
• 210000004165 myocardium Anatomy 0.000 description 1
• 239000007922 nasal spray Substances 0.000 description 1
• 201000009240 nasopharyngitis Diseases 0.000 description 1
• 229930014626 natural product Natural products 0.000 description 1
• 239000006225 natural substrate Substances 0.000 description 1
• 210000003739 neck Anatomy 0.000 description 1
• 230000017074 necrotic cell death Effects 0.000 description 1
• 101150091879 neo gene Proteins 0.000 description 1
• 201000008383 nephritis Diseases 0.000 description 1
• 210000000944 nerve tissue Anatomy 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 201000001119 neuropathy Diseases 0.000 description 1
• 230000007823 neuropathy Effects 0.000 description 1
• 208000015238 neurotic disease Diseases 0.000 description 1
• 108091027963 non-coding RNA Proteins 0.000 description 1
• 102000042567 non-coding RNA Human genes 0.000 description 1
• 235000016709 nutrition Nutrition 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 238000010915 one-step procedure Methods 0.000 description 1
• 238000001543 one-way ANOVA Methods 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 239000000668 oral spray Substances 0.000 description 1
• 210000004789 organ system Anatomy 0.000 description 1
• 201000008482 osteoarthritis Diseases 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• 238000012261 overproduction Methods 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 238000004806 packaging method and process Methods 0.000 description 1
• 230000000242 pagocytic effect Effects 0.000 description 1
• 201000002528 pancreatic cancer Diseases 0.000 description 1
• 208000008443 pancreatic carcinoma Diseases 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 210000002990 parathyroid gland Anatomy 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 230000006320 pegylation Effects 0.000 description 1
• 210000004197 pelvis Anatomy 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 208000028169 periodontal disease Diseases 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 208000027232 peripheral nervous system disease Diseases 0.000 description 1
• 210000004303 peritoneum Anatomy 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 239000012071 phase Substances 0.000 description 1
• 238000002205 phenol-chloroform extraction Methods 0.000 description 1
• 229960005190 phenylalanine Drugs 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• 150000003905 phosphatidylinositols Chemical class 0.000 description 1
• 229940080469 phosphocellulose Drugs 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 238000005222 photoaffinity labeling Methods 0.000 description 1
• 238000013081 phylogenetic analysis Methods 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 230000019612 pigmentation Effects 0.000 description 1
• 210000003635 pituitary gland Anatomy 0.000 description 1
• 210000001778 pluripotent stem cell Anatomy 0.000 description 1
• 229920000656 polylysine Polymers 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 230000035935 pregnancy Effects 0.000 description 1
• 208000012113 pregnancy disease Diseases 0.000 description 1
• 230000013823 prenylation Effects 0.000 description 1
• 108010066381 preproinsulin Proteins 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 239000004018 propan-1,2-diol esters of fatty acids Substances 0.000 description 1
• 239000000473 propyl gallate Substances 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 235000019419 proteases Nutrition 0.000 description 1
• 230000012743 protein tagging Effects 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 239000012264 purified product Substances 0.000 description 1
• 229940043131 pyroglutamate Drugs 0.000 description 1
• 230000006340 racemization Effects 0.000 description 1
• 230000001172 regenerating effect Effects 0.000 description 1
• 230000006884 regulation of angiogenesis Effects 0.000 description 1
• 230000014493 regulation of gene expression Effects 0.000 description 1
• 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
• 102000037983 regulatory factors Human genes 0.000 description 1
• 108091008025 regulatory factors Proteins 0.000 description 1
• 230000008844 regulatory mechanism Effects 0.000 description 1
• 230000008439 repair process Effects 0.000 description 1
• 238000012827 research and development Methods 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 230000001177 retroviral effect Effects 0.000 description 1
• 238000004007 reversed phase HPLC Methods 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 201000003068 rheumatic fever Diseases 0.000 description 1
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
• 230000033764 rhythmic process Effects 0.000 description 1
• 238000007363 ring formation reaction Methods 0.000 description 1
• 201000005404 rubella Diseases 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• 231100000241 scar Toxicity 0.000 description 1
• 230000037390 scarring Effects 0.000 description 1
• 230000037387 scars Effects 0.000 description 1
• 102000014452 scavenger receptors Human genes 0.000 description 1
• 108010078070 scavenger receptors Proteins 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 230000036303 septic shock Effects 0.000 description 1
• 238000007493 shaping process Methods 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 239000002002 slurry Substances 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 210000002460 smooth muscle Anatomy 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
• 239000004296 sodium metabisulphite Substances 0.000 description 1
• 239000001488 sodium phosphate Substances 0.000 description 1
• 229910000162 sodium phosphate Inorganic materials 0.000 description 1
• 235000011008 sodium phosphates Nutrition 0.000 description 1
• 210000004872 soft tissue Anatomy 0.000 description 1
• 238000010532 solid phase synthesis reaction Methods 0.000 description 1
• 230000003381 solubilizing effect Effects 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 239000008174 sterile solution Substances 0.000 description 1
• 239000000021 stimulant Substances 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• 210000002536 stromal cell Anatomy 0.000 description 1
• 238000012916 structural analysis Methods 0.000 description 1
• 125000001424 substituent group Chemical group 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 239000001797 sucrose acetate isobutyrate Substances 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 229910052717 sulfur Inorganic materials 0.000 description 1
• 239000004173 sunset yellow FCF Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 230000008961 swelling Effects 0.000 description 1
• 210000001179 synovial fluid Anatomy 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 208000006379 syphilis Diseases 0.000 description 1
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 229910052713 technetium Inorganic materials 0.000 description 1
• GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
• 201000004415 tendinitis Diseases 0.000 description 1
• 201000003120 testicular cancer Diseases 0.000 description 1
• 229960002180 tetracycline Drugs 0.000 description 1
• 229930101283 tetracycline Natural products 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
• 229940126585 therapeutic drug Drugs 0.000 description 1
• 230000001225 therapeutic effect Effects 0.000 description 1
• 229960002898 threonine Drugs 0.000 description 1
• 210000001541 thymus gland Anatomy 0.000 description 1
• 239000003104 tissue culture media Substances 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 230000005026 transcription initiation Effects 0.000 description 1
• 230000005030 transcription termination Effects 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 230000007704 transition Effects 0.000 description 1
• 230000014616 translation Effects 0.000 description 1
• 230000014621 translational initiation Effects 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 230000000472 traumatic effect Effects 0.000 description 1
• YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 1
• 229950004616 tribromoethanol Drugs 0.000 description 1
• ZSDSQXJSNMTJDA-UHFFFAOYSA-N trifluralin Chemical compound CCCN(CCC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O ZSDSQXJSNMTJDA-UHFFFAOYSA-N 0.000 description 1
• HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
• 229940038773 trisodium citrate Drugs 0.000 description 1
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 201000002311 trypanosomiasis Diseases 0.000 description 1
• 230000005748 tumor development Effects 0.000 description 1
• 230000005751 tumor progression Effects 0.000 description 1
• 201000008297 typhoid fever Diseases 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 208000019206 urinary tract infection Diseases 0.000 description 1
• 229960005486 vaccine Drugs 0.000 description 1
• 208000007089 vaccinia Diseases 0.000 description 1
• 229960004295 valine Drugs 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 230000006496 vascular abnormality Effects 0.000 description 1
• 230000007556 vascular defect Effects 0.000 description 1
• 239000005526 vasoconstrictor agent Substances 0.000 description 1
• 201000009371 venous hemangioma Diseases 0.000 description 1
• 230000007998 vessel formation Effects 0.000 description 1
• 230000009278 visceral effect Effects 0.000 description 1
• 230000000007 visual effect Effects 0.000 description 1
• 238000011179 visual inspection Methods 0.000 description 1
• 229940088594 vitamin Drugs 0.000 description 1
• 229930003231 vitamin Natural products 0.000 description 1
• 235000013343 vitamin Nutrition 0.000 description 1
• 239000011782 vitamin Substances 0.000 description 1
• 239000012610 weak anion exchange resin Substances 0.000 description 1
• 239000012224 working solution Substances 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1
• 230000004572 zinc-binding Effects 0.000 description 1